首页 >> 中文 >> 专家人才

专家人才

  • 姓名: 张天宇
  • 性别: 男
  • 职称: 研究员
  • 学历: 博士
  • 电话: 
  • 传真: 
  • 电子邮件: zhang_tianyu@gibh.ac.cn
  • 通讯地址 广州市开源大道190号A132

    简历:

  •  

       广东特支计划“科技创新领军人才”(2016) ,呼吸疾病国家重点实验室结核病研究室联合主任。中国科学技术大学、安徽大学教授,博士生导师。专注结核病(TB),特别是抗TB治疗研究13年。在构建抗TB药物筛选、评价模型及药效评估方面已取得丰硕的成果,部分研究处于世界先进水平,合作研发的1个抗TB新候选药已申报国家发明专利1项和PCT 1项并转让给企业(之后对新的适应症又申报了2项专利和1PCT)。在TB诊断及药物敏感性检测方面取得了突破性进展(尚未发表,已申报国家发明专利和PCT1项)。在对结核分枝杆菌(M. tuberculosis)进行遗传操作,研究抗TB药物的耐药机制和作用机制等方面已取得了显著的成果。此外,还涉及TB治疗性疫苗的研发,已取得初步成果。(个人主页: http://www.scholat.com/tianyuzhang  OR  http://zhangty.gibh.ac.cn/  OR  http://people.ucas.edu.cn/~zhangtyatgibh# 210124)

     

    教育背景

    2005.10-2010.08 美国约翰霍普金斯大学(The Johns Hopkins University)

    医学院(School of Medicine),博士后,师从世界著名TB研究资深专家,前WHO有关TB领域的Chairman, GATB顾问委员会成员的Jacques H Grosset教授和TB药物临床前研究领域的新星Eric Nuermberger 教授(201612月新晋)。后者指导了目前临床实验中的所有TB药的临床前药效学研究。

    2002.08-2005.07 中国医学科学院暨中国协和医科大学,医药生物技术研究所

    微生物与生化药学,博士

    1999.09-2002.07 首都师范大学,生命科学学院,硕士(保送)

    1995.09-1999.07 首都师范大学,生命科学学院,学士(总成绩第一名)

    研究领域:

  •  

    1. 致病菌的后基因组学研究;

    2. 抗致病菌药物研发,药物作用机制与耐药机制的研究;

    3. 致病菌的快速诊断和药敏检测研究;

    4. 细菌与宿主相互作用,疫苗的开发。

    承担科研项目情况:

  •  

    社会任职:

  •  

    获奖及荣誉:

  • 1. 广东省第五届专利奖 优秀奖(2018

    2. 广东特支计划科技创新领军人才”(2016)

     

     

    代表论著:

  • 发表的主要一作或通讯作者文章

    [1] Zhang N, Liu Z, Liang J, Tang Y, Qian Lu, Gao Y, Zhang T*, Ming Yan*. Design, synthesis, and biological evaluation of m-amido phenol derivatives as a new class of antitubercular agents. Med Chem Comm (Accepted)

    [2] Liu P, Yang Y, Ju Y, Tang Y, Sang Z, Chen L, Yang T, An Q, Zhang T, Luo Y*. Design, synthesis and biological evaluation of novel pyrrole derivatives as potential ClpP1P2 inhibitor against. Mycobacterium tuberculosis. Bioinorganic Chemistry 原来名称:Journal of inorganic biochemistry (Accepted).

    [3] Chhotaray C, Tan Y, Mugweru J, Hameed H.M. A., Islam M.M, Wang S, Lu Zh, Wang C, Li X, Tan S, Liu J*, Zhang T*. Advances in development of molecular genetic tools in Mycobacterium tuberculosis. J Genet Genomics. 2018, 45: 281-297.

    [4] Mugweru J, Liu J, Makafe Gaelle, Chiwala G, Wang B, Wang C, Li X, Tan Y, Yew W, Tan S*, Zhang T*. Mutation ethAW21R Confers Co-resistance to Protionamide and Ethionamide in both M. bovis BCG and M. tuberculosis H37Rv. Infect Drug Resist. 2018, 11: 891-894.

    [5] Hameed A, Islam M, Chhotaray C, Liu Y, Tan Y, Li X, Tan S, Chen L, Delorme V, Yew W, Liu J*, Zhang T*. Molecular targets related drug resistance mechanisms in MDR-, XDR- and TDR-Mycobacterium tuberculosis strains. Front Cell Infect Microbiol. 2018, 8:114. 

    [6] Njire M, Wang N, Wang B, Tan Y, Cai X, Julius M, Cai X, Liu Y, Mugweru J, Guo J, Hameed HMA, Tan S, Liu J, Yew W, Nuermberger EL, Lamichhane G, Liu J, Zhang T*. Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 201761(7)e00070-17.

    [7] Mugweru J, Makafe G, Cao Y, Zhang Y, Wang B, Huang S, Njire M, Chotorary C, Tan Y, Li X, Liu J, Tan S, Deng J, Zhang T*. A Cassette Containing Thiostrepton, Gentamicin Resistance Genes and dif sequences is Effective in Construction of Recombinant Mycobacteria. Front Microbiol. 2017, 8:468

    [8] Islam M, Hameed A, Mugweru J, Chhotaray C, Wang C, Tan Y, Liu J, Li X, Tan S, Ojima I, Yew W, Zhang T*. Drug Resistance Mechanisms and Novel Drug Targets for Tuberculosis Therapy. J Genet Genomics. 2017, 44:21-37.

    [9] Guo J, Wang C, Han Y, Liu Z, Wu T, Liu Y, Liu Y, Tan Y, Cai X, Cao Y, Wang B, Zhang B, Liu C, Tan S and Zhang T*. Identification of Lysine Acetylation in Mycobacterium abscessus Using LC-MS/MS after Immunoprecipitation. J Proteome Res. 2016. 15(8):2567-2578. (DOI: 10.1021/acs.jproteome.6b00116).

    [10] Tan S*, Rao Y, Guo J, Tan Y, Cai X, Kuang H, Li Y, Liu W, Mugweru J, Wang B, Cao Y, Wang C, Zhang Y, Zhang T*.The Influence of Pyrazinamide Monoresistance on Treatment Outcomes in Tuberculosis Patients from Southern China. J Tuberculosis Res. 2016. 4:9-17.

    [11] Makafe G, Cao Y, TanY, Julius M, Liu Z, Wang C, Njire M, Cai X, Liu T, Wang B, Pang W, Tan S, ZhangB, Yew W, Lamichhane G, Guo J, Zhang T*. Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016.60(5):3202-3206.

    [12] Njire M, Tan Y, Mugweru J, Wang C, Guo J, Yew W, Tan S*, Zhang T*. Pyrazinamide resistance in Mycobacterium tuberculosis: review and update. Adv Med Sci. 2016. 61(1):63-71.

    [13] Tang J, Wang B, Wu T, Wan J, Tu Z, Njire M, Wan B, Franzblauc SG, Zhang T*, Lu X*, Ding K*. Design, synthesis and biological evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as novel antitubercular agents. ACS Med Chem Lett. 2015. 6:814-818.

    [14] Liu T, Wang B, Guo J, Zhou Y, Julius M, Njire M, Cao Y, Wu T, Liu Z, Wang C, Xu Y, Zhang T*. Role of folp1 and folp2 genes in the action of sulfamethoxazole and trimethoprim against mycobacteria. J Microbiol Biotechnol. 2015. 25(9):1559-1567.

    [15] Yang F, Njire M, Liu J, Wu T, Wang B, Liu T, Cao Y, Liu Z, Wan J, Tu Z, Tan Y, Tan S, Zhang T*. Engineering more stable, selectable marker-free autoluminescent mycobacteria by one step. PLoS One. 2015. 10(1):e0119341.

    [16] Yang F, Tan YJ, Liu J, Liu TZ, Wang BX, Cao YY, Qu Y, Lithgow T, Tan SY, Zhang T*. Efficient construction of unmarked recombinant mycobacteria using an improved system. J Microbiol Methods. 2014. 103:29-36.

    [17] Tan YJ, Hu ZQ, Zhang T*, Cai XS, Kuang HB, Liu YW, Chen JY, Yang F, Zhang K, Tan SY*, Zhao YL. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China. J Clin Microbiol. 2014. 52(1):291-297.

    [18] Tan S*, Sun D, Zhang T, Li Y, Cao Y, Njire M, Wang C, Zhang T*. Risk factors for hemoptysis in pulmonary tuberculosis patients from southern China: a retrospective study. J Tuberculosis Res. 2014. 2:173-180.

    [19] Zhang T, Li SY, Converse PJ, Grosset JH, Nuermberger EL*. Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection. PLoS Negl Trop Dis. 2013.7(12):e2598.

    [20] Chen C, Lu M, Liu Z, Wan J, Tu Z, Zhang T*, Yan M*. Synthesis and evaluation of 2-amino-4h-pyran-3-carbonitrile derivatives as antitubercular agents. Open J Med Chemi. 2013. 3: 128-135.

    [21] Zhang T, Li SY, Nuermberger EL*. Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy. PLoS One. 2012. 7:e29774.  

    [22] Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL*. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med. 2011. 184:732-737.

    [23] Zhang T, Li SY, Converse PJ, Almeida DV, Grosset JH, Nuermberger EL*. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection. Antimicrob Agents Chemother. 2011. 55:56-61.

    [24] Zhang T, Bishai WR, Grosset JH, Nuermberger EL*. Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrob Agents Chemother. 2010. 54(7): 2806-2813.

    [25] Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL*. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med. 2009. 180: 1151-1157.

    [26] Zhang T, Wang LXu GChen YZhang YLi Y*. Disruption of ste23 gene affects composition profile and bioactivity of exopolysaccharide produced by Streptomyces sp. 139. Lett App Microbiol. 2006, 42(2):132-137.

    [27] Zhang T, Wang LXu GChen YZhang YLi Y*. Disruption of the ste22 Gene Encoding a Glycosyltransferase and Its Function in Biosynthesis of Ebosin in Streptomyces sp. 139. Curr Microbiol. 2006, 52(1):55-59.

    [28] 刘志永,王帅,张天宇*,土井教生,谭守勇,谢小保,高亚敏,唐运祥,姜火风,谢武。一种新型医用动态空气消毒机对MTB等病原微生物杀菌效果的研究。中国防痨杂志2018404):411-415

    [29] 刘洋,王邦兴,刘志永,韩轶,谭耀驹,李昕洁,刘健雄,谭守勇*张天宇*。非一线抗结核药物耐药机制及耐药性诊断研究进展。遗传201638 (10):928-939

    [30]张天宇,谢建平,王明贵。抗生物耐药性研究领域的机遇和挑战。遗传201638 (10):857-858

    [31] 梁镇兴,张可,谭耀驹,谭守勇,张天宇*。利用自主发光结核分枝杆菌快速连续检测抗结核药物的细胞内活性。实用医学杂志201329 (23): 209-212

    已发表的主要共同作者文章 (仅列出2014年后的)

    [1] Wang T, Tang Y, Yang Y, An Q, Sang Z, Yang T, Liu P, Zhang T, Deng Y, LuoY. Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold. Bioorg Med Chem Lett. 2018, 28(11): 2084-2090.

    [2] Feng P, Ma G, Zhang T, Wang C. Copper-Catalyzed Direct C-H Bond Arylation of Benzoxazoles with Anilines. Asian J. Org. Chem. 2018, 7: 788-792. 2018 Feb 19 online DOI:10.1002/ajoc.201800002.

    [3] Yang S, Hu Y, Wang X, GaoY, Li K, Zhang X, Chen S, Zhang T, Gu J, Deng J. Deletion of sigB Causes Increased Sensitivity to para-Aminosalicylic Acid and Sulfamethoxazole in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2017, 61(10):e00551-17.

    [4] Ma J, Huang H, Xie Y, Liu Z, Zhao J, Zhang C, Jia Y, Zhang Y, Zhang H, Zhang T, Ju J. Biosynthesis of ilamycins featuring unusual building blocks and engineered production of enhanced anti-tuberculosis agents. Nat Commun. 2017, 8(1):391.

    [5] Lu X, Tang J, Cui S, Wan B, Franzblauc S, Zhang T, Zhang X, Ding K. Pyrazolo [1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity. E J Med Chem. 2017. 125: 41-48.

    [6] Lu X, Hu X, Liu Z, Zhang T,Wang R, Wan B, Franzblaud S,You Q. Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug susceptible and resistant Mycobacterium tuberculosis. Med Chem Comm 2017.8(6).

    [7] He W, Zhou XJ Qin X, Mai Y, Lin X, Liao S, Yang B, Zhang T, Tu Z, Wang J, Liu Y. Quinone/hydroquinone meroterpenoids with antitubercular and cytotoxic activities produced by the sponge-derived fungus Gliomastix sp. ZSDS1-F7. Nat Prod Res. 2017, 31(5):604-609.

    [8] Lu X, Tang J, Liu Z, Li M, Zhang T, Zhang X, Ding K. Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis. Bioorg Med Chem Lett. 2016, 26(24):5916-5919.

    [9] Saremi L, Saremi M, Lotfipanah S, Mani S, Fu J, Zhang T. Correlation between HFE gene polymorphisms and increased risk of coronary artery disease among patients with type 2 diabetes in Iran. Turk J Med Sci. 2016,46(3):590-596.

    [10] Wang J, Wei X, Qin X, Tian X, Liao L, Li K, Zhou X, Yang X, Wang F, Zhang T, Tu Z, Chen B, Liu Y. Antiviral Merosesquiterpenoids Produced by the Antarctic Fungus Aspergillus ochraceopetaliformis SCSIO 05702. J Nat Prod. 2016, 79(1):59-65.

    [11] Tian Y, Lin X, Wang Z, Zhou X, Qin X, Kaliyaperumal K, Zhang T, Tu Z, Liu Y. Asteltoxins with Antiviral Activities from the Marine Sponge-Derived Fungus Aspergillus sp. SCSIO XWS02F40. Molecules. 2015, 21(1):E34.

    [12] Saremi L, Saremi M, Lotfipanah S, Imani S, Zhang T, Fu J. Relationship between PPARGC1A Gene Polymorphisms with the Increased Risk of Coronary Artery Disease among Patients with Type 2 Diabetes Mellitus in Iran. Acta Endo (Buc) 2015, 11 (1): 13-17.

    [13] Wang J, Qin X, Xu F, Zhang T, Liao S, Lin X, Yang B, Liu J, Wang L, Tu Z,Liu Y. Tetramic acid derivatives and polyphenols from sponge-derived fungus and their biological evaluation. Nat Prod Res. 2015.9:1-5.

    [14] Wang J, We X, Qin X, Chen H, Lin X, Zhang T, Yang X, Liao S, Yang B, Liu J, Zhou X, Tu Z, Liu Y. Two new prenylated phenols from endogenous fungus Pestalotiopsis vaccinii of mangrove plant Kandelia candel (L.) Druce. Phytochem Lett. 2015.12: 59–62.

    [15] Wang J, Wang Z, Ju Z, Wan J, Liao S, Lin X, Zhang T, Zhou X, Chen H, Tu Z, Liu Y. Cytotoxic cytochalasins from marine-derived fungus Arthrinium arundinis. Planta Med. 2015, 81(2):160-166.

    [16] Wang J, Lin X, Qin C, Liao S, Wan T, Zhang T, Liu J, Fredimoses M, Chen H, Yang B, Zhou X, Yang X, Tu Z, Liu Y. Antimicrobial and Antiviral Sesquiterpenoids from Sponge-Associated Fungus, Aspergillus sydowii ZSDS1-F6. J Antibiot. 2014, 67(8):581-583.  

    [17] Sun J, Lin X, Zhou X, Wan T, Zhang T, Yang B, Yang X, Tu Z, Liu Y. Pestalols A-E, New Alkenyl Phenol and Benzaldehyde Derivatives from Endophytic Fungus Pestalotiopsis sp. Acbc2 Isolated from the Chinese Mangrove Plant. Aegiceras corniculatum. J Antibiot. 2014.67:451-457.  

    [18] Wang J, Xu F, Wang Z, Lu X, Wan J, Yang B, Zhou X, Zhang T, Tu Z, Liu Y.  A new naphthalene glycoside from the sponge-derived fungus Arthrinium sp. ZSDS1-F3. Nat Prod Res. 2014,16:1-5.

    [19] Fang W, Lin X, Zhou X, Wan J, Lu X, Yang B, Ai W, Lin J, Zhang T, Tu Z, Liu Y. Cytotoxic and antiviral nitrobenzoyl sesquiterpenoids from the marine-derived fungus Aspergillus ochraceus Jcma1 F17. Med. Chem. Commun. 2014,5:701-705.

    [20] Yang Z, Li R, Zhang T. Evolution of influenza a H7N9 virus with an emphasis on gene constellation. J Genet Genomics. 2014,41:3-6.

    [21]卢峰岳,张天宇,谭耀驹,蔡杏珊,胡族琼,刘燕文,苏碧仪。吡嗪酰胺敏感性检测结果应该运用到对结核病治疗。广东医学。201536 (10): 1509-1511

     

    申请的发明专利

    美国专利:

    Eric Nuermberger, Tianyu Zhang, Jacques Grosset.Autoluminescent mycobacterial reporter strains2011, patent number: (61/367,475).

    PCT

    [1] 陆小云,汤健,丁克,张天宇,涂正超,伍甜,万军庭,曹元元。吡唑并[1,5-a]吡啶类化合物及其应用,2015PCT (CN2015/086852)

    [2] 张天宇,刘志永。一种可投送自主发光元件的分枝杆菌噬菌体及其应用,2016PCTCN2016/081202

    [3] 张天宇,刘洋。一种吡啶类化合物的新用途(2018,专利申请号:PCTCN2018/077992)。(申请提交日:2018-03-05)。

    中国专利:

    [1] 张天宇,杨峰,刘佳。整合质粒pOPHI及无抗性筛选标记的自主发光分枝杆菌(2012, 专利号:ZL 201210183007.2。授权证书号:1296049, 授权公告日:2013-10-30

    [2] 张天宇,杨峰,邹文英。一种用于高效构建无抗性标记重组分枝杆菌的抗性表达盒(2013,专利号:ZL 201310386264.0。授权证书号:1799902, 授权公告日:2015-09-23

    [3] 朱强,张天宇,刘兰英,鲁明辉,毛婷婷,黄金波。吲哚[3,2-c]喹啉类化合物或其药学上可接受的盐及其制备方法和应用(2013),ZL 201310385431.X。授权证书号:2017232, 授权公告日:2016-04-06

    [4] 丁克,陆小云,张天宇,汤健,鲁明辉,李宇鹏,张章,梁镇兴,钱政江。N-4-三氟甲基苯基水杨酰胺衍生物的制备方法和应用(2014),专利申请号:201410073672.5

    [5] 陆小云,汤健,丁克,张天宇,涂正超,伍甜,万军庭,曹元元。吡唑并[1,5-a]吡啶类化合物及其应用(2014),专利申请号:201410562805.5 [优先权专利号更改为2015104607516]

    [6] 张天宇,曹元元,伍甜,谭守勇,谭耀驹,蔡杏珊,刘春平。构建无选择标记的自主发光脓肿分枝杆菌的方法及建立相应体外高通量筛药模型(2015),专利申请号:ZL 201510104936.3(2018.06.01已授权)

    [7] 张天宇,刘志永。一种可投送自主发光元件的分枝杆菌噬菌体及其应用(2016)专利申请号:201610127984.9[抗结核候选药怡莱霉素申请了专利(201610885104.4)及发表了高水平的论文(Nat. Commun., 2017, 8, 391),研究成果发表以后受到了国家新华网、科技日报、国家自然科学基金委等国家级媒体的报道,并被收录国家自然科学基金委资助成果一书及入选“中国海洋与湖沼学会“2017年十大科技进展”]

    [8] 鞠建华,马俊英,张天宇,刘志永。一种海洋链霉菌及其环肽化合物在制备抗结核分枝杆菌药物中的应用(2016),专利申请号:201610255638.9

    [9] 张天宇,摩西·M·恩扎瑞,王邦兴,刘志永,韩轶,刘燕,刘洋。一种检测结核分支杆菌耐药性的DNA标记物及其应用(2016)专利申请号:201610564946.X

    [10] 涂正超(475345840 (美国护照),朱强,张天宇,黄金波,徐晓冰,万军庭,黎敏科,李登科,周亚丽,刘志永,王邦兴,米琦.托特雷拉。吲哚-2--3-螺噻嗪酮或噻唑酮化合物及其应用(2016),专利申请号:2016106571617 (申请提交日:2016-8-11)

    [11] 张天宇, 马格文如.朱丽俄斯,刘燕,王邦兴,曹元元,黄少波,玛卡芬.盖乐, 张洋,郭锦涛,柴然吉比.筹多拉瑞,刘洋。一种硫链丝菌素-庆大霉素抗性基因体系及含有其的抗性表达盒和重组质粒(2016),专利申请号:201610902985.6(申请提交日:2016-10-18,发文序号:2016101801161450)(公告日:专利申请公布和进入实质审查日:2017-05-17

    [12] 张天宇,刘洋,谭守勇,刘健雄,李昕洁,王邦兴,周佩佩,蔡杏珊,郭玲敏,刘燕,刘志永,唐运祥,高亚敏,姜火凤。吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的药物组合物(2017),专利申请号:201710240224.3(申请提交日:2017-04-13)

    [13] 王子厚,张天宇,马领弟,陈昌红。蜡梅属植物抗结核杆菌的用途(2017),专利申请号:201710392913.6(申请提交日:2017-05-27)

    [14] 鄢明,张天宇,张妞妞,刘志永,钱露,唐运祥,程亚娟,张学景。间二取代苯酚化合物及其制备方法与抗结核菌应用(2017),专利申请号:201711310722.7。(申请提交日:2017-12-11)。

    [15] 罗有福,张天宇。新型小分子化合物、制备方法及在制备抗耐药结核分枝杆菌等分枝杆菌药物方面的用途(2018,专利申请号:201810003576.1。(申请提交日:2018-01-04)。

    [16] 张天宇,刘洋。一种吡啶类化合物的新用途(2018,专利申请号:201810106538.9。(申请提交日:2018-02-02)。

    [17] 张天宇,刘燕,孙彩军,潘恩祥,王邦兴,郭灵敏,陈凌,刘志永。一种艾滋病疫苗及其制备方法(2018,专利申请号:201810359440.4。(申请提交日:2018-04-20)。

    [18] 罗有福,张天宇。嘧啶类小分子化合物及在制备抗分枝杆菌药物中的用途(2018),专利申请号:201810574690.X。(申请提交日:2018-06-06)。